Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Peter Kar Han Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Richard J. Young, Amir Iravani, Hanxian Aw Yeang, Ismael A. Vergara, David Kok, Kate Drummond, Paul Joseph Neeson, Karen E. Sheppard, Tony PapenfussBenjamin J. Solomon, Shahneen Sandhu, Grant A. McArthur

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)'. Together they form a unique fingerprint.

Medicine & Life Sciences